Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
ImmuCell delivered a strong first quarter in 2026, underscoring the earnings power and cash-flow potential of its core First Defense franchise after the company’s strategic exit from Re-Tain. Product sales increased...
— Sean Kirkwood
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on ImmuCell Corporation
ImmuCell is a $65mm market cap animal health company whose core franchise is the First Defense line of products, which protect newborn calves against scours, a leading cause of death for young calves.
ImmuCell Corporation ($ICCC) is an animal health company focused on preventing scours in newborn dairy and beef cattle through its flagship First Defense product line. The manager holds...
More institutional theses from SRK Capital
Vaso Corporation is executing an unusual SPAC merger to uplist from OTCQX to Nasdaq, implying a pro forma value of $0.93 per share compared to its recent $0.28 market price. The structural transaction...
Innovative Solutions & Support offers ~20% organic growth supplemented by a high-return bolt-on acquisition strategy that leverages unutilized manufacturing capacity. Its recent acquisition...
Sigmatron International trades at under one-third of book value and 3x normalized earnings due to current cyclical weakness in consumer electronics manufacturing. Significant working capital...